tetano
Editor, Senior Moderator
Cell Rep
. 2023 Dec 19;43(1):113596.
doi: 10.1016/j.celrep.2023.113596. Online ahead of print. The HLA-II immunopeptidome of SARS-CoV-2
Shira Weingarten-Gabbay[SUP] 1 [/SUP], Da-Yuan Chen[SUP] 2 [/SUP], Siranush Sarkizova[SUP] 3 [/SUP], Hannah B Taylor[SUP] 3 [/SUP], Matteo Gentili[SUP] 3 [/SUP], Gabrielle M Hernandez[SUP] 3 [/SUP], Leah R Pearlman[SUP] 3 [/SUP], Matthew R Bauer[SUP] 4 [/SUP], Charles M Rice[SUP] 5 [/SUP], Karl R Clauser[SUP] 3 [/SUP], Nir Hacohen[SUP] 6 [/SUP], Steven A Carr[SUP] 3 [/SUP], Jennifer G Abelin[SUP] 3 [/SUP], Mohsan Saeed[SUP] 2 [/SUP], Pardis C Sabeti[SUP] 7 [/SUP]
Affiliations
Targeted synthetic vaccines have the potential to transform our response to viral outbreaks, yet the design of these vaccines requires a comprehensive knowledge of viral immunogens. Here, we report severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) peptides that are naturally processed and loaded onto human leukocyte antigen-II (HLA-II) complexes in infected cells. We identify over 500 unique viral peptides from canonical proteins as well as from overlapping internal open reading frames. Most HLA-II peptides colocalize with known CD4[SUP]+[/SUP] T cell epitopes in coronavirus disease 2019 patients, including 2 reported immunodominant regions in the SARS-CoV-2 membrane protein. Overall, our analyses show that HLA-I and HLA-II pathways target distinct viral proteins, with the structural proteins accounting for most of the HLA-II peptidome and nonstructural and noncanonical proteins accounting for the majority of the HLA-I peptidome. These findings highlight the need for a vaccine design that incorporates multiple viral elements harboring CD4[SUP]+[/SUP] and CD8[SUP]+[/SUP] T cell epitopes to maximize vaccine effectiveness.
Keywords: CD4(+) T cell; CP: Immunology; CP: Microbiology; HLA-II; SARS-CoV-2; antigen processing and presentation; immunity; immunopeptidome; noncanonical protein; viral antigen.
. 2023 Dec 19;43(1):113596.
doi: 10.1016/j.celrep.2023.113596. Online ahead of print. The HLA-II immunopeptidome of SARS-CoV-2
Shira Weingarten-Gabbay[SUP] 1 [/SUP], Da-Yuan Chen[SUP] 2 [/SUP], Siranush Sarkizova[SUP] 3 [/SUP], Hannah B Taylor[SUP] 3 [/SUP], Matteo Gentili[SUP] 3 [/SUP], Gabrielle M Hernandez[SUP] 3 [/SUP], Leah R Pearlman[SUP] 3 [/SUP], Matthew R Bauer[SUP] 4 [/SUP], Charles M Rice[SUP] 5 [/SUP], Karl R Clauser[SUP] 3 [/SUP], Nir Hacohen[SUP] 6 [/SUP], Steven A Carr[SUP] 3 [/SUP], Jennifer G Abelin[SUP] 3 [/SUP], Mohsan Saeed[SUP] 2 [/SUP], Pardis C Sabeti[SUP] 7 [/SUP]
Affiliations
- PMID: 38117652
- DOI: 10.1016/j.celrep.2023.113596
Targeted synthetic vaccines have the potential to transform our response to viral outbreaks, yet the design of these vaccines requires a comprehensive knowledge of viral immunogens. Here, we report severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) peptides that are naturally processed and loaded onto human leukocyte antigen-II (HLA-II) complexes in infected cells. We identify over 500 unique viral peptides from canonical proteins as well as from overlapping internal open reading frames. Most HLA-II peptides colocalize with known CD4[SUP]+[/SUP] T cell epitopes in coronavirus disease 2019 patients, including 2 reported immunodominant regions in the SARS-CoV-2 membrane protein. Overall, our analyses show that HLA-I and HLA-II pathways target distinct viral proteins, with the structural proteins accounting for most of the HLA-II peptidome and nonstructural and noncanonical proteins accounting for the majority of the HLA-I peptidome. These findings highlight the need for a vaccine design that incorporates multiple viral elements harboring CD4[SUP]+[/SUP] and CD8[SUP]+[/SUP] T cell epitopes to maximize vaccine effectiveness.
Keywords: CD4(+) T cell; CP: Immunology; CP: Microbiology; HLA-II; SARS-CoV-2; antigen processing and presentation; immunity; immunopeptidome; noncanonical protein; viral antigen.